Compare Tango Therapeutics Inc. (TNGX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Wells Fargo & Co — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Wells Fargo & Co trades at $81.23 (market cap $242.35B). The key difference: Wells Fargo & Co is far larger — about 64.6× Tango Therapeutics Inc.'s market cap, and Wells Fargo & Co pays a 2.48% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Wells Fargo & Co for 88 Days on average.
| TNGX | WFC | |
|---|---|---|
Market Cap | $3.75B | $242.35B |
Volume | 9,619,106 | 25,561,701 |
Sector | Health | Financials |
52-Week High | $32.90 | $96.40 |
52-Week Low | $7.50 | $73.42 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $2.77B | $424.64B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Wells Fargo (WFC) trades at $80.91, down 2.88% on the day, amid mixed technical signals with a bullish overall trend but bearish moving averages. The bank shows strong fundamentals with a P/E of 11.74, net income margin of 25.97%, and consistent earnings beats in recent quarters. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and renewed technology agreements supporting mortgage servicing.
The stock presents a value opportunity with a consensus price target of $98.75, implying 22% upside, supported by analyst bullishness (46.66% buy ratings). Key risks include volatile cash flows, with operating cash flow negative in 2025, and sensitivity to interest rate changes as highlighted by recent Fed hikes (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
